Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59<sup>ES</sup>

Received February 16, 2015; accepted May 7, 2015

ABSTRACT

CYP2C9, one of the most important drug-metabolizing enzymes, is responsible for metabolizing approximately 15% of clinically important drugs, including warfarin, diclofenac, and losartan. Similar to other CYP members, human CYP2C9 exhibits marked genetic polymorphisms among individuals of different ethnicities. In this study, a novel missense mutation (1300A>T) was identified in a warfarin-sensitive patient after a genetic screen of three candidate genes related to high variability in response to warfarin doses. This base transversion leads to an Ile-to-Phe amino acid substitution at codon 434 within the CYP2C9 protein, and this new variant has been named a novel allele, CYP2C9*59, by the Human CYP Allele Nomenclature Committee (http://www.cypalleles.ki.se/cyp2c9.htm). The exogenous expression of CYP2C9*59 in insect cell microsomes revealed that, despite a similar protein expression level as wild-type CYP2C9, variant CYP2C9*59 exhibited significantly reduced maximal velocity, \( V_{\text{max}} \), and/or increased Michaelis constant, \( K_{\text{m}} \), values toward three CYP2C9-specific substrates. Our data suggest that the 1300A>T mutation can greatly decrease the enzymatic activity of the CYP2C9 protein both in vitro and in vivo.

Introduction

CYP2C9 is the major CYP2C isoform in humans and is responsible for the metabolism of approximately 15% of all clinically important drugs (Samer et al., 2013; Chen et al., 2014). Similar to other CYP members, CYP2C9 is highly polymorphic across various racial and ethnic populations. These genetic polymorphisms have been shown to have clinical importance, leading to great inter-individual variability and serious adverse effects in the efficacies of many therapeutic drugs (Chaudhry et al., 2014). Alleles CYP2C9*2 (containing a R144C substitution) and CYP2C9*3 (containing an I359L substitution) have been well studied among different ethnic populations. They have been identified as the most common defective alleles and have exhibited reduced metabolic activities, both in vitro and in vivo, for the CYP2C9 substrates, such as warfarin. In addition to these two common alleles, other allelic variants, such as CYP2C9*4 (Lee et al., 2007), CYP2C9*5 (Dickmann et al., 2001), CYP2C9*8 (Liu et al., 2012), CYP2C9*11 (Tai et al., 2005), CYP2C9*12 (O’Brien et al., 2013), CYP2C9*14 (Lee et al., 2014), CYP2C9*35 (Cicciacci et al., 2011), CYP2C9*57 (Nahar et al., 2013), and CYP2C9*58 (Luo et al., 2014), were reported to affect warfarin sensitivity. In this study, we present the case of a Chinese warfarin-sensitive patient who requires only one-half of the normal oral warfarin dose. Genetic analysis in that patient revealed an absence of the common mutations in CYP2C9 (*2, *3, VKORC1 (rs9923231 and rs7294), and CYP4F2 (rs2108622)) that are usually related to warfarin sensitivity. However, a novel missense mutation (1300A>T) was identified in exon 9 of the CYP2C9 gene. In the vitro functional assessment of this newly found CYP2C9 variant revealed that the substitution of an Ile to a Phe at codon 434 significantly reduced the enzymatic activity of this variant toward all of the tested substrates.

Materials and Methods

Study Subject. The study subject was a 47-year-old male Han Chinese patient who has taken warfarin since his mitral valve replacement surgery in 2012. Initially, the patient was prescribed an average oral dose of warfarin that is suitable for most Chinese individuals (3.0 mg/d). Three days later, the international normalized ratio (INR) value reached 4.35, which is higher than the recommended value. Subsequently, the patient stopped taking the drug for several days to let the INR value decrease to a value of approximately 2. Next, his dosage was reduced to 2 mg/d for the following 3 days. Nonetheless, this lower dose resulted in an INR value that was as high as 3.23. Over the next 3 weeks, the warfarin dose was gradually decreased and adjusted down to 1.5 mg/d for maintenance, stabilizing the INR value between 2.00 and 2.80.

Genotyping. This study was approved by the Institutional Ethical Committee of Beijing Hospital and informed written consent was obtained from the patient during blood sample collection. The genomic DNA extracted from the peripheral blood cells of the subject, using the TIANamp Blood DNA Midi Kit (TIANGEN, Beijing, China), was used for the polymerase chain reaction amplification of the promoters or exons of the CYP2C9, VKORC1, and CYP4F2 genes according to the methods reported previously (Yuan et al., 2005; Burmester et al., 2011; Dai et al., 2014). To avoid sequencing errors, bidirectional sequencing was performed for the putatively mutated sites.

Construction of the Expression Vectors. Site-directed mutagenesis of each CYP2C9 variant was accomplished using the overlap-extension polymerase chain reaction amplification method according to the protocols reported previously (Dai et al., 2014; Luo et al., 2014). Detailed information for all of the other primers is illustrated in Supplemental Table 1. The full-length sequence of each CYP2C9 allele was purified, digested, and cloned into the receptor vector pFastBac-oxidoreductase (OR) to produce the ultimate dual-expression vector pFastBac-OR-CYP2C9, as described previously (Dai et al., 2013).

Recombinant CYP Expression in Insect Microsomes. The pFastBac-OR-CYP2C9 vectors were packaged into baculoviruses. Then, the CYP2C9 variants and OR were simultaneously expressed at high levels in insect microsomes,
according to the manufacturer’s procedure. The determination and quantification of expressed proteins were performed via immunoblotting, as reported previously (Dai et al., 2013). Briefly, 2 μg of microsomes were used for the immunoblotting analysis using a rabbit polyclonal anti-CYP2C9 antibody (AbD Serotec, Oxford, United Kingdom) as the primary antibody at a dilution of 1:1000. The recombinant CYP2C9 Baculosome reagent from BD Gentest (Woburn, MA) was co-analyzed as the microsomal protein standard. The immunoblots were visualized using a Super Signal West Pico Trial Kit (Thermo Fisher Scientific, Rockford, IL), and the band densities were determined using the ImageJ software (National Institutes of Health, Bethesda, MA).

Enzymatic Activity Assay Using Typical CYP2C9 Probe Substrates. To gain a better understanding of the enzymatic characteristics of the newly identified CYP2C9 variants, three different CYP2C9-specific probe substrates (tolbutamide, losartan, and diclofenac) were included in the in vitro experiments, as described previously (Dai et al., 2013; Luo et al., 2014; Wang et al., 2014). The reaction mixtures contained 4–20 pmol of CYP2C9 insect microsome, 8–40 pmol of cytochrome b5 (CYP2C9/b5 = 1:2), 50 mM (for losartan) or 100 mM (for tolbutamide and diclofenac) of Tris-HCl (pH 7.5), and a series of different concentrations of drugs (10–1000 μM for tolbutamide, 0.5–25 mM for losartan, and 1–100 μM for diclofenac). Briefly, the reaction mixtures were preincubated for 5 minutes at 37°C. Then, a NADPH regenerating system was added to start the reaction in a final volume of 200 μl, and the hydroxylation reactions were incubated at 37°C for 60, 30, or 20 minutes for tolbutamide, losartan, or diclofenac, respectively. Then, the reaction was terminated by the addition of 1 ml of acidified ethyl acetate for extraction. The organic layer was evaporated to dryness and reconstituted in 100 μl of mobile phase for high-performance liquid chromatography analysis. The kinetic parameters (Michaelis constant, K<sub>m</sub>, and maximal velocity, V<sub>max</sub>) were estimated using the GraphPad Prism program, version 6.01 (GraphPad Software, San Diego, CA), with nonlinear regression analysis using a hyperbolic Michaelis-Menten equation. The kinetic data are presented as the mean ± S.D. for three independent microsomal preparations derived from separate transfections for wild-type and variant CYPs, and significant differences in CYP2C9s were analyzed by one-way analysis of variance followed by a post hoc test using the IBM SPSS software, version 16.0 (IBM, Armonk, New York).

Results and Discussion

Identification of the New CYP2C9 Variant *59. The subject only required half of the oral amount of warfarin that is commonly used for most Chinese individuals. It has been reported that the CYP2C9*2, *3, and VKORC1 (rs9923231) can explain approximately 49% of the dose requirement variations for long-term treatment with warfarin (Tatarunas et al., 2014). In the present study, we screened the coding regions and promoter sequences in CYP2C9, VKORC1, and CYP4F2 genes, and none of the reported mutations (CYP2C9*2, CYP2C9*3, rs9923231, rs7294, and rs2108622) could be detected in this warfarin-sensitive patient. However, a new nonsynonymous mutation, 1300A>T, was identified in the CYP2C9 gene. As illustrated in Fig. 1A, the subject carried a heterozygous A-to-T mutation in exon 9 of CYP2C9 at position 1300, resulting in Ile (I)-to-Phe (F) substitution at codon 434. The newly found mutation was confirmed by sequence alignment and by searching against the public databases at the National Center for Biotechnology Information. Then, it was submitted to the Human CYP Allele Nomenclature Committee and was named the novel allele CYP2C9*59 (http://www.cypalleles.ki.se/cyp2c9.htm).

Fig. 1. Discovery and functional assessment of novel variant CYP2C9*59. (A) Sanger sequencing result of CYP2C9*59 allele in a warfarin-sensitive Chinese Han patient. The red arrow shows the heterozygous site, the red rectangle shows codon 434, and the black rectangle shows the Ile-to-Phe substitution. (B) Immunoblotting analysis of exogenously expressed CYP2C9 and OR proteins in insect cell microsomes. Commercially available insect microsomes from BD Biosciences (Woburn, MA) and the microsomes from cells transfected with the pFastBac-OR vector were used as the positive and negative controls, respectively. (C) Michaelis-Menten kinetics for the hydroxylation of tolbutamide by the recombinant wild-type and variant CYP2C9s. Plots for diclofenac and losartan are omitted here and detailed kinetic parameters for all three probe substrates are listed in Table 1. Each point represents the means ± S.D. of three independent experiments.
Expression of Wild-Type and Variant CYP2C9s in Insect Cell Microsomes. To gain insight into the metabolic characteristics of the novel CYP2C9 variant, the insect cell expression system was used to simultaneously express the recombinant CYP2C9 variants and the NADPH-cytochrome P450 OR according to the methods described previously (Dai et al., 2013). As shown in Fig. 1B, both OR and CYP2C9s could be highly expressed in insect microsomes, with a similar expression level between the wild-type and the other two variants. These data suggest that the Ile-to-Phe amino acid residue substitution at position 434 has no effect on the expression level of CYP2C9 enzyme in insect cells.

Functional Characterizations of CYP2C9 Allelic Variants. As reported previously, the SF21 insect cell is not a perfect expression system for in vitro warfarin metabolic analysis because an unexpected product could be produced after the incubation of S-warfarin with the recombinant CYPs, even with intact SF21 insect cells (Luo et al., 2014). Therefore, three other typical CYP2C9-specific substrates were included in the metabolic activity assessments. As shown in Fig. 1 and Table 1, the typical variant CYP2C9.3 exhibited approximately 8.6%–38.9% of the enzymatic activity of wild-type CYP2C9.1 toward tolbutamide, diclofenac, and losartan. When expressed in insect cell microsomes, previous reports revealed that typically defective variant CYP2C9.3 exhibited higher V_max values than the wild-type enzyme for the hydroxylation of probe drugs diclofenac and losartan (Dickmann et al., 2001; Maekawa et al., 2009). Our data were quite consistent with those observed in previous studies. For the novel variant CYP2C9.59, our results showed that only 6.1%–18.7% of activity of wild-type enzyme were retained for the hydroxylation of probe drugs tolbutamide, diclofenac, or losartan. These data suggested that the Ile-to-Phe substitution at position 434 significantly decreased the metabolic activity of CYP2C9 protein. The present subject carrying the CYP2C9*1/*59 genotype only requires 50% of the warfarin dose that is required in Chinese individuals harboring the wild-type genotype, whereas previous reports revealed that carriers with CYP2C9*1/*3 genotype required a 33.7% lower warfarin dose than individuals harboring the wild-type *1/*1 genotype (Lam and Cheung, 2012). This result suggests that subjects carrying the CYP2C9*59 allele need lower doses of warfarin than those with the defective allele CYP2C9*3. Consequently, the variant CYP2C9.59, containing an I434F substitution, might exhibit lower enzymatic activity than variant CYP2C9.3 in vivo, which is well in accordance with the results that we have obtained in vitro.

An inspection of the crystal structure of the human CYP2C9 protein (PDB ID: 1OG5) revealed that Cys435 has a central role in the interaction with the heme group, and that the residue Arg433 also contributes to the stabilization of the heme group via hydrogen bonds (Williams et al., 2003). In addition to these two residues, Val436 and G437 also interacted with the heme group when the crystal structure was analyzed using the protein structure homology modeling system SWISS-MODEL Work-space (Biasini et al., 2014). Figure 2 illustrates that Ile434 is located near the heme group and forms a hydrogen-bonding ion pair with Val436.

Genetic Distribution of CYP2C9*59. To better investigate the allele distribution pattern of this newly identified mutation, another group of 50 patients with lower warfarin dosage were enrolled for sequencing of exon 9 in CYP2C9. No carriers were found to harbor the novel allele CYP2C9*59. The NHLBI GO ESP Exome Variant Server (http://evs.gs.washington.edu/EVS/) is one public website for listing novel rare variants found in recent sequencing studies on very large numbers of individuals. However, newly found CYP2C9 allelic variant *59 is not included in this database, which infers that this novel variant is absent or hard to be detected in European and African Americans. Additionally, we recently analyzed the CYP2C9 genetic polymorphisms in 2127 healthy Chinese
individuals and failed to identify the CYP2C9*59 allele in this population (Dai et al., 2014). These data suggest that the estimated allele frequency of this newly found CYP2C9 variant is no more than 0.1% among the general Chinese subjects and should be considered as a rare allele in the Chinese population. Despite this fact, the identification of this novel mutation is still significant for clinical practice in China because more than 1.3 billion people live in mainland China, and the novel variant CYP2C9.59 exhibits a dramatically reduced enzymatic activity that is even lower than that of the typically defective variant CYP2C9.3, as shown both in vitro and in vivo.

In summary, CYP2C9*59 (1300A>T, I434F), a new variant allele, was identified in a warfarin-sensitive Chinese patient. By expression in insect cell microsome, recombinant variant CYP2C9.59 exhibited significantly reduced catalytic activities toward tolbutamide, diclofenac, and losartan, and these activities were even lower than those measured for the common defective variant CYP2C9.3. Our data suggest that the substitution of an amino acid residue is shown with different colors and the hydrogen bond interactions are illustrated with green dashed lines.

Acknowledgments
The authors thank the members of the Beijing Institute of Geriatrics of the Ministry of Health for advice and assistance.

The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, China (D.-P.D., J. C., J.-P.C.);
The Clinical Laboratory of the Beijing Hospital, Ministry of Health, Beijing, China (C.-B.L.);
Department of Pharmacology, School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, China (J.C., H.W., G.-X.H.);
and The Laboratory of Clinical Pharmacy, The People’s Hospital of Lishui, Lishui, Zhejiang, China (S.-H.W., P.-W.G.)

Authorship Contributions
Participated in research design: J.-P. Cai, Hu, Dai.


Wrote or contributed to the writing of the manuscript: Dai, S.-H. Wang, Li.

References

Acknowledgments
The authors thank the members of the Beijing Institute of Geriatrics of the Ministry of Health for advice and assistance.

The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, China (D.-P.D., J. C., J.-P.C.);
The Clinical Laboratory of the Beijing Hospital, Ministry of Health, Beijing, China (C.-B.L.);
Department of Pharmacology, School of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, China (J.C., H.W., G.-X.H.);
and The Laboratory of Clinical Pharmacy, The People’s Hospital of Lishui, Lishui, Zhejiang, China (S.-H.W., P.-W.G.)

Authorship Contributions
Participated in research design: J.-P. Cai, Hu, Dai.


Wrote or contributed to the writing of the manuscript: Dai, S.-H. Wang, Li.